Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EASY: Evaluation of Single Daily Doses of Immunosuppressive Drugs After Liver Transplantation
NCT06354179Phase 4Recruiting
- Sponsor
- CHU de Limoges
- Start
- Apr 2025
- Primary completion
- Apr 2028
- Modality
- RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of Envarsus XR and mycophenolate mofetil in Liver transplant rejection (4 arms), sponsored by CHU de Limoges. Primary endpoint: Incidence of treatment failure at 12 months. Started Apr 2025; status: recruiting.
02
Drugs
Envarsus XRmycophenolate mofetil
03
Conditions
Liver transplant rejection
Beyond the preview
Go deeper on NCT06354179.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06354179.